You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Merck
Boehringer Ingelheim
Dow
AstraZeneca

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Litigation Details for ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD. (D.N.J. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD. (D.N.J. 2016)

Docket   Start Trial Date Filed 2016-12-07
Court District Court, D. New Jersey Date Terminated 2018-10-09
Cause 15:1126 Patent Infringement Assigned To John Michael Vazquez
Jury Demand None Referred To Mark Falk
Parties ABRAXIS BIOSCIENCE, LLC; CELGENE CORPORATION; CIPLA LTD.
Patents 6,096,331; 6,179,817; 6,197,051; 6,506,405; 6,537,579; 6,565,842; 6,749,868; 6,753,006; 7,820,788; 7,923,536; 8,138,229; 8,257,733; 8,268,348; 8,314,156; 8,853,260
Attorneys ALYSON LYNN WOOTEN; ARNOLD B. CALMANN; CATHERINE THISBE MATTES; CHARLES MICHAEL LIZZA; KATHERINE ANN ESCANLAR; PETER LOUIS GIUNTA; SARAH ANN SULLIVAN; WILLIAM C. BATON
Firms K & L Gates LLP; Kilpatrick Townsend & Stockton LLP; Quinn Emanuel Urquhart & Sullivan, LLP; Saul Ewing Arnstein & Lehr LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .
Biologic Drugs cited in ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD. (D.N.J. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-12-07 1 This patent is subject to a terminal dis- 6,096,331 A 8/2000 …than about 1 micron. The use of speci?c 6,096,331. …2011/0118342 A1 5/2011 D6 6t 31. 6,096,331 A 8/2000 Desai et 3L …7,923,536 (the “’536 patent”), 8,138,229 (the “’229 patent”), and 8,853,260 (the “’260 patent”), all owned … 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C External link to document
2018-10-09 123 Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 7,$20,78$, 7.923,536, $,13$,229, and … 4. Until expiration of the Patents-in-Suit. Cipla, including any of its successors…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through Case 2:16-cv…parties in connection with any infringement of the Patents-in-Suit by any such third parties. cinless and…C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit. 9. Nothing herein External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
AstraZeneca
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.